Ray Dogum
Ray Dogum is the Chief Editor of Drug Discovery Online, where he curates and leads editorial content focused on the earliest phases of drug development—from target identification and hit discovery to preclinical validation. With a background in chemical engineering and master's degrees in business and information systems from Boston University’s Questrom School of Business, Ray brings a cross-disciplinary perspective to the future of therapeutic innovation.
Ray’s career has spanned the cutting edge of healthcare and technology. At Amwell, he implemented telehealth solutions integrating medical devices and digital platforms across major US health systems. At Vibe Bio, he launched a biotech-focused podcast and newsletter, driving engagement for the company’s AI-powered pipeline analysis platform. He’s also consulted with senior pharma executives on decentralized ledger technology and led a proof-of-concept to streamline patient-centric clinical trial pre-screening.
Earlier in his career, Ray helped launch and manage a stem cell biology lab at MIT’s Koch Institute, where he supported research into the role of diet in aging and metabolic disease. Ray is also the creator and host of Health Unchained, a podcast exploring how blockchain, AI, and frontier technologies are transforming healthcare. Through in-depth interviews with researchers, entrepreneurs, and investors, he has built a resource that bridges the gap between emerging tech and real-world healthcare applications.
Passionate about enabling collaboration across disciplines, Ray is committed to helping scientists, startups, and innovators tell the stories behind their breakthroughs, shaping the conversation at the intersection of science, technology, and human health. You can often find Ray at local Boston events, staying close to the pulse on the latest discoveries and connecting with the vibrant biotech community.
Connect with Ray Dogum on LinkedIn: https://www.linkedin.com/in/raydogum/
ARTICLES BY RAY DOGUM
-
![GettyImages-518355640]( "Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)")
Why Ending Rh Disease Requires More Than A Breakthrough (Part 3 of 3)8/5/2026Rh disease has been preventable for decades. Yet babies still die worldwide because access, supply, and infrastructure have not caught up.
-
![GettyImages-1200601391]( "Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit")
Chinese Competition And The Future Of Science: Insights From The U.S. Science Summit7/24/2026At BiotechTV’s U.S. Science Summit, biotech leaders discussed China, AI, scientific storytelling, and what it will take to protect U.S. innovation.
-
![GettyImages-505846204]( "Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)")
Rhogam's Unconventional History And Why There Is No True Synthetic Replacement (Part 2 of 3)7/17/2026Rhogam transformed Rh disease prevention, but its plasma-derived, polyclonal biology has resisted decades of synthetic anti-D replacement efforts.
-
![GLP-1 injector pen-GettyImages-2196049876]( "iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody")
iBio Aims To Complement GLP-1s By Preserving Muscle During Weight Loss With Myostatin Antibody6/25/2026iBio has started clinical trials with a long-acting myostatin/GDF11 antibody that can make weight loss healthier and more durable for patients taking GLP-1 agonists.
-
![GettyImages-887028706]( "How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 of 3)")
How Rh Incompatibility Endangers Pregnancies And How Rhogam Helped My Family (Part 1 of 3)6/15/2026Rh incompatibility can make pregnancy dangerous. Rhogam helped protect my family and stands as a powerful example of unconventional drug discovery.
-
![Arvin S]( "2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics")
2026 Nucleate Boston Activator Cohort Interview: Arvin Soepriatna — TEEM Therapeutics6/12/2026Arvin Soepriatna's TEEM Therapeutics is building predictive 3D human heart tissue models to improve cardiac drug screening, reduce risk earlier, and better flag cardiotoxicity.
-
![image-(5)]( "2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics")
2026 Nucleate Boston Activator Cohort Interview: Ryan Posey & Anusha Manglik — Resilientia Therapeutics6/11/2026Startup founders of Resilientia Tx discuss protecting cancer patients from radiation side effects, organ-on-a-chip discovery, Nucleate Boston, and early startup challenges.
-
![Chat_Jayasuriy]( "2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio")
2026 Nucleate Boston Activator Cohort Interview: Dr. Chathuraka Jayasuriya — EnkaBio6/11/2026Dr. Chat Jayasuriya discusses EnkaBio’s meniscus repair therapy, fundraising, Nucleate’s impact, CEO search, and tech transfer from Brown/Rhode Island Hospital.
-
![Chris_Clifford]( "2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics")
2026 Nucleate Boston Activator Cohort Interview: Chris Clifford — Mimic Therapeutics6/10/2026Chris Clifford, founder of Mimic Therapeutics, describes the company’s mission as protecting cell therapies from immune rejection, with an initial focus on Type 1 diabetes.
-
![Carlos_Ezio]( "2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore")
2026 Nucleate Boston Activator Cohort Interview: Carlos Ezio — Criocore6/10/2026Carlos Ezio, co-founder and CEO of Criocore, a Harvard Medical School spinout developing bioprinted and frozen human tissue models for preclinical development.
